HK Stock Market Move | INNOVENT BIO (01801) continues to rise by over 3%. The company's commercial performance last year was remarkable, and 6 new products will be launched and sold in the next 25 years.

INNOVENT BIO (01801) continued to rise by over 3%, as of the time of writing, it had risen by 3.49% to HKD 37.5 with a trading volume of HKD 1.6 billion. China Securities Co., Ltd. issued a research report stating that the company's product revenue in 2024 exceeded 8.2 billion yuan, maintaining strong growth of over 40% year-on-year, with impressive commercial performance and sales meeting market expectations. Based on this, the company will launch 6 new products for sale in 2025, and with the success of evolocumab (PCSK9) entering the medical insurance catalog, the company's commercial performance in 2025 is expected to improve. Overall, the company's commercial performance continues to be impressive and steadily progresses towards the target of 20 billion yuan in domestic revenue by 2027, with good prospects for its future development. The report also noted that the company's extensive layout in the field of oncology has begun to take shape, with high-value clinical products expected to further increase revenue in the oncology field and keep marginal costs down. In non-oncology areas, the company has made extensive layouts in the fields of metabolism, immunology, and ophthalmology, with both listed and under-research products being competitive and ahead in progress.